“Whether and How the U.S. Government Should Exercise Its Compulsory Licensing Authority Under 28 U.S.C. § 1498 and the Bayh-Dole Act”

  • Intellectual Property and Antitrust
New York University Journal of Intellectual Property and Entertainment Law
2021

“Cannabis for Medical Use: FDA and DEA Regulation in the Hall of Mirrors”

  • Health Law
Food and Drug Law Journal
2019

“A Functional Approach to Judicial Review of PTAB Rulings on Mixed Questions of Law and Fact”

  • Intellectual Property and Antitrust
Iowa Law Review
2019

“Opting Into Device Regulation in the Face of Uncertain Patentability”

  • Intellectual Property and Antitrust
  • Law and Technology
Marquette Intellectual Property Law Review
2019

“Promoting Healthcare Innovation on the Demand Side”

  • Intellectual Property and Antitrust
  • Law and Technology
Journal of Law and the Biosciences
2017

“Insurance for broad genomic tests in oncology”

  • Health Law
Science
2017

“Diagnostics Need Not Apply”

  • Intellectual Property and Antitrust
  • Law and Technology
Boston University Journal of Science & Technology Law
2015

“Wisdom of the Ages or Dead-Hand Control? Patentable Subject Matter for Diagnostic Methods After In Re Bilski”

  • Intellectual Property and Antitrust
Case Western Reserve Journal of Law, Technology & the Internet
2012

“Patent Costs and Unlicensed Use of Patented Inventions”

  • Intellectual Property and Antitrust
University of Chicago Law Review
2011

“Pharma’s Nonobvious Problem”

  • Intellectual Property and Antitrust
Lewis and Clark Law Review
2008

“Noncompliance, Nonenforcement, Nonproblem? Rethinking the Anticommons in Biomedical Research”

  • Intellectual Property and Antitrust
Houston Law Review
2008

“The Supreme Court and the Federal Circuit: Visitation and Custody of Patent Law”

  • Intellectual Property and Antitrust
Michigan Law Review First Impressions
2007

“The Role of the FDA in Innovation Policy”

  • Intellectual Property and Antitrust
Michigan Telecommunications and Technology Law Review
2007

“Harnessing and Sharing the Benefits of State-Sponsored Research: Intellectual Property Rights and Data Sharing in California’s Stem Cell Initiative”

  • Intellectual Property and Antitrust
Berkeley Technology Law Journal
2006

“BioTech. Patents: Looking Backward While Moving Forward”

  • Intellectual Property and Antitrust
Nature Biotechnology
2006

“Patents and Data-Sharing in Public Science”

  • Intellectual Property and Antitrust
Industrial and Corporate Change
2006

“Learning the Value of Drugs - Is Rofecoxib a Regulatory Success Story?”

  • Health Law
New England Journal of Medicine
2005

“The Problem of New Uses”

  • Health Law
Yale Journal of Health Policy, Law, and Ethics
2005

“Reexamining Drug Regulation from the Perspective of Innovation Policy”

  • Health Law
Journal of Institutional and Theoretical Economics
2004

“Obvious to Whom? Evaluating Inventions from the Perspective of PHOSITA”

  • Intellectual Property and Antitrust
Berkeley Technology Law Journal
2004

“Patenting Genome Research Tools and the Law”

  • Intellectual Property and Antitrust
Comptes rendus Biologies
2003

“Patent Swords and Shields”

  • Intellectual Property and Antitrust
Science
2003

“Patents, Product Exclusivity, and Information Dissemination: How Law Directs Biopharmaceutical Research and Development”

  • Intellectual Property and Antitrust
Fordham Law Review
2003

“Bayh-Dole Reform and the Progress of Biomedicine”

  • Intellectual Property and Antitrust
Law and Contemporary Problems
2003

“Bayh-Dole Reform and the Progress of Biomedicine”

  • Intellectual Property and Antitrust
American Scientist
2003

“How Can You Patent Genes?”

  • Intellectual Property and Antitrust
American Journal of Bioethics
2002

“Public vs. Proprietary Science: A Fruitful Tension?”

  • Intellectual Property and Antitrust
Academic Medicine: Journal of the Association of American Medical Colleges
2002

“Why the Gene Patenting Controversy Persists”

  • Intellectual Property and Antitrust
Academic Medicine: Journal of the Association of American Medical Colleges
2002

“Public vs. Proprietary Science: A Fruitful Tension?”

  • Intellectual Property and Antitrust
Daedalus
2002

“The Shifting Functional Balance of Patents and Drug Regulation”

  • Intellectual Property and Antitrust
Health Affairs
2001

“Analyze This: A Law and Economics Agenda for the Patent System”

  • Intellectual Property and Antitrust
Vanderbilt Law Review
2000

“Re-Examining the Role of Patents in Appropriating the Value of DNA Sequences”

  • Intellectual Property and Antitrust
Emory Law Journal
2000

“Genomics in the Public Domain: Strategy and Policy”

  • Intellectual Property and Antitrust
Nature Reviews Genetics
2000

“The Promise and Perils of Strategic Publication to Create Prior Art: A Response to Professor Parchomovsky”

  • Intellectual Property and Antitrust
Michigan Law Review
2000

“National Policy Perspectives-Streamlining the Transfer of Research Tools”

  • Intellectual Property and Antitrust
Academic Medicine: Journal of the Association of American Medical Colleges
1999

“Can Patents Deter Innovation? The Anticommons on Biomedical Research”

  • Intellectual Property and Antitrust
Science
1998

“Upstream Patents = Downstream Bottlenecks”

  • Intellectual Property and Antitrust
Law Quadrangle Notes
1998

“Do EST Patents Matter?”

  • Intellectual Property and Antitrust
Trends in Genetics
1998

“Focus on Faculty - Rebecca S. Eisenberg”

Law Quadrangle Notes
1998

“Structure and Function in Gene Patenting”

  • Intellectual Property and Antitrust
Nature Genetics
1997

“Public Research and Private Development: Patents and Technology Transfer in Government-Sponsored Research”

  • Intellectual Property and Antitrust
Virginia Law Review
1996

“Intellectual Property at the Public-Private Divide: The Case of Large-Scale cDNA Sequencing”

  • Intellectual Property and Antitrust
University of Chicago Law School Roundtable
1996

“Intellectual Property Issues in Genomics”

  • Intellectual Property and Antitrust
Trends in Biotechnology
1996

“Opinion Letter as to the Patentability of Certain Inventions Associated with the Identification of Partial cDNA Sequences”

  • Intellectual Property and Antitrust
AIPLA Quarterly Journal
1995

“Reply to Comments on the Patentability of Certain Inventions Associated with the Identification of Partial cDNA Sequences”

  • Intellectual Property and Antitrust
AIPLA Quarterly Journal
1995

“Limiting the Role of Patents in Technology Transfer”

  • Intellectual Property and Antitrust
Law Quadrangle Notes
1994

“Technology Transfer and the Genome Project: Problems with Patenting Research Tools”

  • Intellectual Property and Antitrust
Risk: Health, Safety and Environment
1994

“A Technology Policy Perspective on the NIH Gene Patenting Controversy”

  • Intellectual Property and Antitrust
University of Pittsburgh Law Review
1994

“Limiting the Role of Patents in Technology Transfer”

  • Intellectual Property and Antitrust
Chemtech
1993

“Limiting the Role of Patents in Technology Transfer”

  • Intellectual Property and Antitrust
Journal of NIH Research
1993